Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart...
Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients
News | Heart Failure | September 04, 2019
September 4, 2019 – Novartis announced results from two new clinical trials evaluating improvement in heart structure...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
August 27, 2019 — Imagine there were a drug that you could take soon after a heart attack that could reduce damage by...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
August 23, 2019 – Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after...
Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can...
Statins Reduce Stroke, Cardiovascular Risk in Cancer Patients Following Radiation
News | Cardio-oncology | July 29, 2019
July 29, 2019 — Cancer patients taking cholesterol-lowering statin medication following radiation therapy of the chest...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
July 26, 2019 — A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies...
Videos | Atrial Fibrillation | June 21, 2019
Sanjaya Gupta, M.D., electrophysiologist, St. Luke's Mid America Heart Institute, and assistant professor, University...
Global Afib Patient Registry Shows New Tools Needed to Assess Patient Risk
News | Patient Engagement | June 17, 2019
June 17, 2019 – Initial results from the AVIATOR 2 international registry were presented as late-breaking clinical...
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
June 14, 2019 — Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its...
Boston Scientific Initiates OPTION Trial of Watchman FLX
News | Left Atrial Appendage (LAA) Occluders | June 12, 2019
June 12, 2019 — Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next-...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
May 29, 2019 — Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S. Food and Drug Administration (FDA) this week approved Fragmin (dalteparin sodium) injection,...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (...